Skip to main content

Dr. Jonathan L. Berkowitz, M.D., PH.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
21
In the NPI registry since
2007
Medicare patients seen, 2024
362

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Medical school: State University of New York at Buffalo School of Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    IN license 01081263A
  • Hematology (Internal Medicine) Physician
    IN license 01081263A
  • Hematology & Oncology Physician
    CA license A116529

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
362
Services billed
1,350
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes891258
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or166100
Smoking and tobacco use intensive counseling, 4-10 minutes10135
Established patient office or other outpatient visit, 30-39 minutes7965
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg6325
Injection of drug or substance under skin or into muscle6325
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2920
Advance care planning, first 30 minutes2622
New patient office or other outpatient visit, 60-74 minutes2424

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 2 payments worth $48.79 in total to this clinician.

By company
Acrotech Biopharma Inc.$25.08
Novartis Pharmaceuticals Corporation$23.71
By type
Education$25.08
Food and Beverage$23.71

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 15, 2025Acrotech Biopharma Inc.
Jan 15, 2025
Education
BELEODAQ · ONCOLOGY · in-kind
$25.08

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Indiana →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $50,721 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
    Merck Sharp & Dohme LLC
  • A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
    Genentech, Inc.
  • Phase 2 Multicenter Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd DS-8201a) for the Treatment of Selected HER2 Expressing Tumours (DESTINY-PanTumor02)
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Muncie

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 4, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1609070671. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.